Market Access NICE and the controversy over a ‘clinically distinct disease... Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.
Market Access Transformative trends with real-world data from early access... The complex and changing needs of patients with life-threatening conditions has led many health authorities to introduce early access programmes.
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
